Hancock, MD , Aug. 16, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, issues a shareholder letter to update investors on recent advancement in the company.
Dear Fellow Shareholder,
It has been an exciting few months at your company.
In a very short time we have revitalized the company by adding a new management team and have worked tirelessly to revamp our upcoming new website. We have initiated an entirely new social media campaign and have seen our stock price move steadily upward. We have welcomed many new investors. This is all great news for Pets and Pet Lovers.
Our new media campaigns have worked to educate the public about the risk of cancer in their companion animals while at the same time creating excitement about what Petlife will bring to the market in the future.
We at Petlife are excited about the rebranding of our flagship product (Escozine for PetsTM) and will soon be announcing our new branding strategy for our product line.
Most importantly is that through our engagement of Innovision Therapeutics we have started on our pathway towards seeking approval of Escozine for PetsTM as an FDA approved product for cancer treatment in certain types of cancer seen in companion animals. Innovision has registered many drugs successfully with the FDA and has specific experience and knowledge with Escozine. The formal announcement of this collaboration will be forthcoming. As we move down this pathway Petlife Pharmaceuticals will be seeking approval for other forms of cancer and will begin to investigate Escozine’ s use in other disease states. The possibility of addressing other diseases is very promising and we look forward to potential news regarding these additional applications.
Our journey, like any other noble quest, will not yield instantaneous results but we have advanced a reasonable timeline based upon the respected input of our Advisory Board and Chief Medical Officer. These individuals all have significant experience in the approval process for oncology drugs and have worked successfully with Escozine in several international markets.
I am grateful that you are part of this exciting journey. I look forward to working for you to create a healthy future for our pets and a healthy financial future for our shareholders.
Best Regards,
Ralph T. Salvagno M.D., CEO and Chairman of the Board
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.
PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets — Escozine for Pets™. It is based on the same patented ‘Escozine for Humans’ formula that has been sold by affiliated companies worldwide in 40 countries. Escozine for Pets™ uses a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.
PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.
Safe Harbor
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.
CONTACT: Investor Relations: Invicto Group info@invictogroup.com 800-928-7462 Ext. 801
